Drugs seized from US manufacturer for cGMP violations
This article was originally published in SRA
Federal law enforcement officers, at the request of the US Food and Drug Administration, have seized some 33 drug products in multiple strengths, as well as raw ingredients, from Caraco Pharmaceutical Laboratories’ plants in Detroit, Farmington Hills and Wixom, Michigan1. The FDA says the firm has not taken appropriate steps to correct violations of current good manufacturing practices at these locations.
You may also be interested in...
Pink Sheet reporters and editor discuss President-Elect Joe Biden’s decision to name the CDER director as acting FDA commissioner and other staffing changes, as well as changes to industry trade groups’ political donations.
Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials.
US Ninth Circuit affirms a district court’s summary judgment in favor of Target and manufacturer of Up & Up brand biotin supplement it sells. Indian manufacturer targeted in putative class-action in New York prompted FDA’s 2016 creation of import alert category for Ayurvedic supplements.